1,048 results on '"Deharo, Jean-Claude"'
Search Results
2. Epidemiology of major heart rhythm and conduction disorders
3. Personalized screening before subcutaneous cardioverter-defibrillator implantation: Usefulness and outcomes in clinical practice—the S-ICD screening SIS prospective study
4. Recommendations of an expert group for the cardiac assessment of non-dystrophic myotonia adult patients treated with mexiletine
5. Distinct Substrates of Idiopathic Ventricular Fibrillation Revealed by Arrhythmia Characteristics on Implantable Cardioverter-Defibrillator
6. Scientific statement from the French neurovascular and cardiac societies for improved detection of atrial fibrillation after ischaemic stroke and transient ischaemic attack
7. Long-term effectiveness and safety of edoxaban in patients with atrial fibrillation: 4-year data from the ETNA-AF-Europe study
8. Expert opinion on mexiletine treatment in adult patients with myotonic dystrophy
9. Atrioventricular conduction disorders in aortic valve infective endocarditis
10. Outcomes Associated With Left Atrial Appendage Occlusion Via Implanted Device in Atrial Fibrillation
11. Les indications de l’ablation de fibrillation atriale
12. Information provision and follow-up of French patients with implantable cardioverter-defibrillators: The APODEC survey
13. Structures de prise en charge : les unités de syncope
14. Sex Differences in Outcomes of Tetralogy of Fallot Patients With Implantable Cardioverter-Defibrillators
15. Outcome of patients with early repolarization pattern and syncope
16. Machine learning–derived major adverse event prediction of patients undergoing transvenous lead extraction: Using the ESC EHRA EORP European lead extraction ConTRolled ELECTRa registry
17. Advantages and disadvantages of drug challenge during electrophysiological study in patients with new left bundle branch block after transaortic valve implantation
18. Prognostic value of ventricular arrhythmia in early post-infarction left ventricular dysfunction: the French nationwide WICD-MI study.
19. Healthcare costs in implantable cardioverter-defibrillator recipients: A real-life cohort study on 19,408 patients from the French national healthcare database
20. Safety, Pharmacokinetic, and Pharmacodynamic Study of a Sublingual Formula for the Treatment of Vasovagal Syncope
21. Discussion à la suite de la présentation: «Les indications de l’ablation de fibrillation atriale»1
22. First Electromyographic Monitoring of a Progressive Phrenic Nerve Palsy in a Pulsed Field Ablation Procedure
23. Prevention of Device Infection: Procedural Aspects, Drugs, and Preventive Tools
24. Prevention of Device Infection: New Implantable Devices
25. Smartwatch Electrocardiogram and Artificial Intelligence for Assessing Cardiac-Rhythm Safety of Drug Therapy in the COVID-19 Pandemic. The QT-logs study
26. Simulation-based training in cardiology: State-of-the-art review from the French Commission of Simulation Teaching (Commission d’enseignement par simulation–COMSI) of the French Society of Cardiology
27. Cardioneuroablation for the treatment of reflex syncope and functional bradyarrhythmias: A Scientific Statement of the European Heart Rhythm Association (EHRA) of the ESC, the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS) and the Latin American Heart Rhythm Society (LAHRS)
28. Two-in-one procedure for transvenous lead extraction and leadless pacemaker reimplantation in pacemaker-dependent patients with device infection: streamlined patient flow.
29. Real-world experience of leadless left ventricular endocardial cardiac resynchronization therapy: A multicenter international registry of the WiSE-CRT pacing system
30. Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis
31. Joint Position Paper of the Working Group of Pacing and Electrophysiology of the French Society of Cardiology and the French Society of Diagnostic and Interventional Cardiac and Vascular Imaging on magnetic resonance imaging in patients with cardiac electronic implantable devices
32. Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France
33. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study
34. Early mortality after implantable cardioverter defibrillator: Incidence and associated factors
35. Diaphragm movement sensor for phrenic nerve monitoring during cryoballoon procedures: the first clinical evaluation
36. The European Society of Cardiology Cardiac Resynchronization Therapy Survey II: A comparison of cardiac resynchronization therapy implantation practice in Europe and France
37. Understanding Outcomes with the EMBLEM S-ICD in Primary Prevention Patients with Low EF Study (UNTOUCHED): Clinical characteristics and perioperative results
38. Efficacy of theophylline in patients with syncope without prodromes with normal heart and normal ECG
39. Implantable cardioverter defibrillator therapy for primary prevention of sudden cardiac death in the real world: Main findings from the French multicentre DAI-PP programme (pilot phase)
40. Exclusion of Intra-Atrial Thrombus Diagnosis Using D-Dimer Assay Before Catheter Ablation of Atrial Fibrillation
41. Different techniques of venous access for CIEDs: advantages and disadvantages
42. Corrigendum to ‘Syncope in hypertrophic cardiomyopathy (part II): An expert consensus statement on the diagnosis and management’ [International Journal of Cardiology, 2023, 41:180–186]
43. Downregulation of ACE2 induces overstimulation of the renin–angiotensin system in COVID-19: should we block the renin–angiotensin system?
44. Prophylactic implantable cardioverter defibrillators for primary prevention: From implantation to heart transplantation
45. Single-Procedure Outcomes and Quality-of-Life Improvement 12 Months Post-Cryoballoon Ablation in Persistent Atrial Fibrillation: Results From the Multicenter CRYO4PERSISTENT AF Trial
46. Emerging concepts in diagnosis and treatment of syncope by pacing
47. Usefulness of a clinical risk score to predict the response to cardiac resynchronization therapy
48. Cardioneuroablation for treatment of atrioventricular block: to cure the patient or the electrocardiogram?
49. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: Developed by the Task Force on cardiac pacing and cardiac resynchronization therapy of the European Society of Cardiology (ESC) With the special contribution of the European Heart Rhythm Association (EHRA)
50. Guía ESC 2021 sobre estimulación cardiaca y terapia de resincronización
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.